Regulatory Query: Response to National Stock Exchange of India Limited letter Ref. No. NSE/CM/Surveillance/17278 dated July 17, 2026
Query Subject: Seeking clarification on news item captioned "Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care" appearing in The Hindu BusinessLine
Company's Clarification on Product Discontinuation
Premarin Vaginal Cream, an imported product, has been temporarily discontinued in India due to certain supply constraints
The Company is actively exploring options to restore the supply at the earliest
The product contributes less than 1% to the revenue of the Company
The temporary discontinuation is not expected to have any material impact on the Company's:
Financial performance
Business operations
Profitability
Regulatory Compliance Reference
The temporary discontinuation of the product did not constitute a material event requiring disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015
The Company remains committed to making timely disclosures of all material events and information in accordance with applicable legal and regulatory requirements
